Processa Pharmaceuticals

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal #Cancer https://lnkd.in/g9MmNAik

Our CEO George Ng will be attending BIO International Convention June 3-6. 2024. Please email [email protected] to set up a meeting. #oncology #cancer #chemotherapy

Our Dr. David Young will be attending The ASCO 2024 Annual Meeting May 31 - June 4. If you'd like to meet while there, please email us per the below. #Cancer #Oncology #ASCO2024

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference https://lnkd.in/gMYvHydR

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research https://lnkd.in/eJi6FC6W

"For #cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary. They’ve ignited a movement to radically change how new cancer drugs are tested, with the U.S. Food and Drug Administration urging drugmakers to do a better job at finding the lowest effective dose, even if it takes more time." We recently presented the poster presentation, titled “Next generation capecitabine (NGC-Cap) in Phase 1b trial significantly increases 5-FU exposure while improving safety profile compared to capecitabine,” reporting the following recent findings: 18 patients were enrolled in the first four dose levels of capecitabine in NGC-Cap The 5-FU exposure, expressed as the area under the 5-FU plasma concentration curve or AUC (geometric mean, CV%), for the two highest doses cohorts of 150 and 225 mg twice-daily NGC-Cap were 4,551 (26.8%) and 6,889 (41.4%) ng-hr/ml, respectively, which is approximately 5-10 times the AUC (0-inf) of 698 (33%) previously reported for a larger dose of approximately 2,250 mg twice-daily of monotherapy capecitabine (Reigner 1998) Similarly, the 5-FU maximum plasma concentrations (Cmax) for these two cohorts were greater at 1.5 times the Cmax of monotherapy capecitabine As expected, with the greater 5-FU exposure for all the NGC-Cap cohorts, the incidence of anabolite related side effects was also greater than monotherapy treatment, suggesting that more drug was distributed to duplicating cancer cells and normal cells The extremely low FBAL catabolite formation and exposure across all NGC-Cap doses resulted in the incidence of catabolite related side effects to be less with only one patient having Grade 1 hand-foot-syndrome, an FBAL related side effect often requiring dose modifications https://lnkd.in/eEkjhwPi

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial https://lnkd.in/dqySVf7y